Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps3-24-05 | Thyroid Eye Disease | ETA2023

Teprotumumab for the treatment of recalcitrant thyroid eye disease

Men Clara , Amarikwa Linus , Sears Connie , Shinder Roman , Clauss Kevin , Ugradar Shoaib , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...

ea0090p750 | Thyroid | ECE2023

Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

Katz Barrett , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Ugradar Shoaib , O'Shaughnessy Denis J. , Summerfelt Rochelle M. , She Angela , Douglas Raymond

Purpose: IGF-1R antagonism reduces TED-related inflammation and proptosis. VRDN-001, a subnanomolar affinity full antagonist antibody to IGF-1R, is being evaluated in a phase 1/2 RCT (NCT05176639) at 3-20 mg/kg. We present results from the first cohort (10 mg/kg) of TED patients.Methods: Adults with active moderate-to-severe TED with clinical activity score (CAS) ≥4 were randomized to 2 infusions 3 weeks apart of either 10 mg/kg VRDN-001 or placebo...

ea0092op-09-01 | Oral Session 9: Thyroid Eye Disease | ETA2023

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

Douglas Raymond , Ugradar Shoaib , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Kossler Andrea , Boisvert Chantal , Lee Wendy , Yen Michael , Kaufman David , Yoon Michael , Bedian Vahe , Katz Barrett

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

ea0092op-04-02 | Oral Session 4: Young Investigators / Clinical and Translational | ETA2023

Teprotumumab-Related adverse events in thyroid eye disease: a multi-center real world study

Shah Shreya , Amarikwa Linus , Sears Connie , Ugradar Shoaib , Clauss Kevin , Rajjoub Raneem , Kang Julia , Tamhankar Madhura , Briceno Cesar , Harrison Andrew , Dosiou Chrysoula , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Objectives: The insulin-like growth factor I receptor (IGF-1R) plays a significant role in the pathology of thyroid eye disease (TED), an autoimmune disorder characterized by orbital inflammation. Teprotumumab, a human monoclonal antibody targeting IGF-1R, has demonstrated efficacy in treating moderate-to-severe TED. A significant proportion of patients experienced adverse events (AEs), with 74% and 85% reporting an AE and 12% and 5% reporting serious AEs in Phase 2 and 3 tria...